Drugs / ORCA-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04097002 | Nov 2019 → Oct 2024 | prostate adenocarcinoma | Orca Therapeutics B.V. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORCA-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04097002 ↗ |
| Route | Other | “intratumoral administration of ORCA-010” NCT04097002 ↗ |